1,755 filings
Page 34 of 88
6-K
x12hun34
24 Apr 14
Pride-hd Study Enrolling Patients Globally to Further Evaluate Pridopidine for the Symptomatic Treatment of Huntington’s Disease
12:00am
6-K
aehf mryb8z9
21 Apr 14
Live Filing
12:00am
6-K
e5ytgg0xfgg st7b
15 Apr 14
Teva Announces Launch of Generic Lunesta® Tablets In the United States
12:00am
6-K
ym2joway 62
8 Apr 14
Teva Announces First Approval and Launch of Generic Lovaza®capsules In the United States
12:00am
6-K
qjnpf
31 Mar 14
Teva Announces U.s. Supreme Court Will Hear Its Appeal on Copaxone® Patent
12:00am
6-K
l8s1d8snfflyv8mjm6xi
20 Mar 14
Live Filing
12:00am
6-K
lkt9vga3cdwekpxci7
13 Mar 14
Live Filing
12:00am
6-K
akcye3l4ty9w
7 Mar 14
Teva Announces Launch of Generic Xeloda® Tablets 150 MG and 500 MG In the United States
12:00am
6-K
rq2qxwdvi vem
4 Mar 14
Teva Announces Approval of Generic Evista® Tablets 60 MG In the United States
12:00am
6-K
3i5xubw7n22u0 36a84e
3 Mar 14
The first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
12:00am
6-K
v8b8mdmea11z1ji3huad
28 Feb 14
Teva to Present at theCowen & Company 34th Annual Healthcare Conference
12:00am
6-K
suf f4689t8uh3348a
24 Feb 14
Teva to Present at theCiti 2014 Global Healthcare Conference
12:00am
6-K
oqu6a avdd
24 Feb 14
Live Filing
12:00am
6-K
g2prhmom zsv
24 Feb 14
Teva Files 2013 Annual Report on Form 20-F
12:00am
SC TO-T/A
hxxd2xe9lpc 8e9
21 Feb 14
Third party tender offer statement (amended)
12:00am
6-K
cj016 44ey
21 Feb 14
Live Filing
12:00am
6-K
kqxs9er9n8hrxr
21 Feb 14
Teva Completes Tender Offer for NuPathe Inc. Shares
12:00am
SC TO-T/A
jxqlca n6cq
14 Feb 14
Third party tender offer statement (amended)
12:00am
6-K
1a1c7d 4f
13 Feb 14
Teva Announces Full Fda Approval of Synribo® (Omacetaxine Mepesuccinate) for Injection
12:00am
SC 13G
hv04pbq clrai4v2ekv
13 Feb 14
Teva Pharmaceutical Industries LTD
12:00am